Abstract:Checkpoint inhibitors have been very successful in various tumors, including melanoma and lung cancer. However, these treatments have failed in other tumors, including pancreatic cancer and glioblastoma. Approaches harnessing the immune response are hindered by multiple factors, including T cell exhaustion. Exhausted T cells are less capable of limiting tumor progression. TOX is particularly important for the transcriptional and epigenetic reprogramming of exhausted T cells, and without TOX, T cells cannot differentiate down the exhaustion pathway. While it is known that NFAT is directly upstream of TOX, our understanding of the pathways that lead to the upregulation of TOX remains incomplete. We hypothesized that tumor necrosis factor (TNF) could be involved in the upregulation of TOX, as TNF has been shown to induce exhaustion and can lead to the translocation of NFAT into the nucleus. While we did not detect an upregulation of the pro-inflammatory TNF receptor type I (TNFR1), we observed significant upregulation of the anti-inflammatory TNF receptor type II (TNFR2) in tumor-infiltrating T cells, but not in lymphoid organs. This local upregulation mimics expression patterns of canonical exhaustion markers and suggests that TNFR2 signaling could be involved in the progression of exhaustion. In support of this hypothesis, TNFR2 expression is correlated other markers of exhaustion, including PD1, TIM3, and TOX. Furthermore, TNFR2 knock out (KO) CD8 T cells have significantly lower expression of TOX, without the concomitant decrease of TIM3. Whereas previous studies have intricately linked TIM3 and TOX expression, these data suggest that TIM3 and TOX are regulated independently. To further evaluate transcriptional regulation of WT and KO T cells, we utilized bulk RNA-sequencing. After performing pathway analyses, we detected a significant reduction of T cell exhaustion, senescence, and immune checkpoint pathways in TNFR2 KO T cells. We identified significant decreases in various exhaustion-related transcription factors and coinhibitory markers. In contrast, we discovered a significant increase in AP1 transcription factors, commonly associated with T cell effector functions. Given this reduced exhaustion profile, we subsequently investigated the influence of TNFR2 on tumor burden. TNFR2 KO mice had significantly less tumor burden following subcutaneous tumor challenges. To make this approach more translatable, we treated mice with a TNFR2 antagonist. While the antagonist alone was not sufficient to improve tumor control, combination with immune checkpoint blockade (anti-PD1) significantly reduced tumor volumes in traditionally resistant models. These data provide evidence for a novel marker of exhaustion that could result in a novel therapeutic strategy. Citation Format: Alexandra Hoyt-Miggelbrink, Jessica Waibl Polania, Aditya Mohan, Luke Wachsmuth, Selena Lorrey, Emily Lerner, Daniel Wilkinson, Andrew Hardigan, Kelly Hotchkiss, Saskia Hemmers, Sarah Cook Quackenbush, Katayoun Ayasoufi, Peter Fecci. TNFR2 is a novel marker of exhaustion and TNFR2 blockade improves subcutaneous tumor control [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A056.

Intermittent administration of tacrolimus enhances \nanti-tumor immunity in melanoma-bearing mice

Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models Through Sustained Antitumor Immunity

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Mycophenolate mofetil enhances the effects of tacrolimus on the inhibitory function of regulatory T cells in patients after liver transplantation via PD-1 and TIGIT receptors

Abstract 7536: CD4+T cell exhaustion in the tumor microenvironment and antitumor immunity

Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hosts

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy

Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion

Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity

Intratumoral antigen signaling traps CD8 + T cells to confine exhaustion to the tumor site

Effect and mechanism of tacrolimus on melanogenesis on A375 human melanoma cells

Abstract 723: Reduction of immunosuppressive function of regulatory T cells enhances antigen-specific T cell mediated cytotoxicity against tumor cells

[Immune regulatory effect of tacrolimus in patients with severe aplastic anemia and in murine model]

Abstract 2635: An epigenetic regulation targeting inhibitory receptors and attenuates CD8 T cell exhaustion in breast cancer

Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity

Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy

Abstract A056: TNFR2 is a novel marker of exhaustion and TNFR2 blockade improves subcutaneous tumor control

IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model

Immu-05. Tnfr2 Is A Novel Marker Of Exhaustion And Tnfr2 Blockade Improves Subcutaneous Tumor Control